Compare Kraft Heinz Co (KHC) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Kraft Heinz Co trades at $22.27 (market cap $26.66B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 2.2× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (7.12%). Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| KHC | TAK | |
|---|---|---|
Market Cap | $26.66B | $58.74B |
Volume | 31,300,109 | 3,110,994 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $19.05 |
52-Week Low | $21.21 | $13.23 |
Typical Hold Time | 129 Days | 1 Days |
Enterprise Value | $42.98B | $86.65B |
Dividend Yield | 7.12% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.48, up 2.27% on the day, with a bearish technical signal and mixed fundamentals. The stock shows a low P/E of 13.04 and P/B of 0.74, but negative net income and ROE reflect profitability challenges. Recent earnings have beaten estimates, and the company maintains a $0.40 dividend. Cash flow improved in 2025, though revenue declined to $24.94 billion. News highlights turnaround efforts, including new product launches and a halted breakup plan.
The outlook is cautious; while valuation appears cheap and dividends attract income investors, persistent negative margins and high debt pose risks. Analyst consensus is mixed with a $24.50 price target, but bearish sentiment and competitive pressures suggest limited near-term upside. Investors should weigh the dividend yield against execution risks in the consumer goods sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
